RESUMEN
The knowledge and training of nursing staff is essential for the safety and comfort of patients receiving i.v. therapies. The use of i.v. bisphosphonates as an adjunct to standard antineoplastic therapies in patients with advanced cancer is becoming widespread. Zoledronic acid and pamidronate (Zometa and Aredia, Novartis Pharmaceuticals Corporation, East Hanover, NJ) are nitrogen-containing bisphosphonates. Pamidronate has been the standard of care for patients with osteolytic bone lesions from breast cancer or multiple myeloma. However, zoledronic acid, which has demonstrated increased potency and a broad clinical utility, is emerging as the new standard of care. In addition to treating hypercalcemia of malignancy, zoledronic acid is approved for treating patients with bone metastases (osteolytic or osteoblastic) from a wide range of solid tumors, including breast, prostate, and lung cancers, or osteolytic bone lesions from multiple myeloma. Zoledronic acid (4 mg via a 15-minute infusion) has a safety profile comparable with pamidronate (90 mg via a two-hour infusion) and has demonstrated comparable or superior efficacy to that of pamidronate in every patient population tested. The shorter infusion time of zoledronic acid compared with that of pamidronate may provide added convenience, but safety guidelines should be followed for all i.v. bisphosphonate therapies. These guidelines and nursing care of patients receiving i.v. bisphosphonates are reviewed.
Asunto(s)
Neoplasias Óseas/tratamiento farmacológico , Neoplasias Óseas/secundario , Difosfonatos/uso terapéutico , Imidazoles/uso terapéutico , Enfermería/métodos , Difosfonatos/administración & dosificación , Humanos , Imidazoles/administración & dosificación , Infusiones Intravenosas , Ensayos Clínicos Controlados Aleatorios como Asunto , Ácido ZoledrónicoRESUMEN
OBJECTIVES: To provide a general overview of tumor lysis syndrome (TLS) focusing on the incidence, epidemiology, and patient outcomes associated with the syndrome; review the role of the oncology nurse in impacting patient outcomes and identify evolving issues relating to TLS. DATA SOURCES: Primary and tertiary literature related to TLS and clinical practice experience. CONCLUSIONS: Issues related to TLS continue to evolve and the oncology nurse plays a key role in patient management. As with other neoplastic disease-related complications (e.g., pain, nausea/vomiting), knowledge of TLS and attention and intervention, where appropriate, can positively impact patient outcome. IMPLICATIONS FOR NURSING PRACTICE: The oncology nurse plays a critical role in impacting patient outcomes with respect to TLS ranging from collaboration with other disciplines to identifying patients at risk, through assessments, vigilant monitoring, and implementing optimal treatment regimens.